Drug
Bendamustine
Bendamustine: highest development phase Phase 3, developed by BeiGene, Bristol-Myers Squibb, Teva. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BeiGene, Bristol-Myers Squibb, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bendamustine HCl NCT00139841 | Phase 3 | Non-Hodgkin's Lymphoma |
| Bendamustine hydrochloride NCT01108341 | Phase 2 | Non-Hodgkin's Lymphoma (NHL) |
| Bendamustine NCT06854003 | Phase 2 | Mantle Cell Lymphoma |
| Bendamustine NCT03739619 | Phase 1/2 | Recurrent Hodgkin Lymphoma |
| Bendamustine NCT01900509 | Phase 1 | Hodgkin Lymphoma |
Latest
No recent events.
Follow Bendamustine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.